Literature DB >> 6537916

Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy.

J P Sculier, D Weerts, J Klastersky.   

Abstract

We reviewed the causes of death of 55 granulocytopenic patients who received empiric antibiotic treatment for fever according to an EORTC cooperative protocol; 53 presented cancer and 2 aplastic anemia. Among the 55 patients, 19 (35%) deaths were attributed to infection: 16 to bacterial and 3 to fungal infections. Among the patients with bacterial infections, 12 died from septic shock, 3 from pneumonia and 1 from Pseudomonas aeruginosa meningitis. The most frequent non-infectious causes of death were the cancer progression (18%) and hemorrhagic complications (27%), most often cerebromeningeal in relationship to thrombocytopenia. A large number of the patients who died from infection (78%) and hemorrhage (74%) had advanced cancer with poor chances to respond to anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6537916     DOI: 10.1016/0277-5379(84)90034-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  22 in total

1.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.

Authors:  P Van der Auwera; J Klastersky; S Lieppe; M Husson; D Lauzon; A P Lopez
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients.

Authors:  A El-Yazigi; M Ellis; P Ernst; D Spence; R Hussain; F J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Superinfections during antimicrobial treatment with betalactam-aminoglycoside combinations in neutropenic patients with hematologic malignancies.

Authors:  P Serra; C Santini; M Venditti; F Mandelli; P Martino
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

7.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.